Regenicin, Inc.
company.status.inactiveCIK 1412659fmd_0ZTH6ZEMGE65ANGEC6GZYZCZR2Manufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Oct 01, 2007 to Mar 31, 2023, 54 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net interest income | – | – | – | – | – | 0 | – | – | – | – |
| Realized investment gains (losses) | – | – | – | (27) | (0) | (3) | – | – | – | – |
| Research and development | 1 | 0 | – | 0 | 0 | 0 | – | – | – | – |
| Total operating expenses | 2 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | (2) | (4) | (1) | (0) | (1) | (1) | (1) | (1) | (1) | (1) |
| Interest expense | (1) | (1) | (0) | (0) | (0) | 0 | 0 | 0 | (0) | (0) |
| Income before taxes | – | (5) | (1) | 3 | (1) | – | – | – | – | – |
| Income tax expense | – | – | (3) | 3 | – | – | – | – | – | – |
| Net income from continuing operations | – | – | 2 | 0 | – | – | – | – | – | – |
| Net income | (3) | (5) | 2 | 0 | 1 | (1) | 1 | 1 | (1) | (1) |
| Net income to common shareholders | (3) | (5) | – | – | – | – | (1) | (1) | (1) | (1) |